KRAS G12V peptide-HLA-A*11:01 complex

The KRAS G12V peptide-HLA-A*11:01 complex is a molecular structure in which a 9-mer peptide containing the cancer-driving KRAS G12V mutation (most commonly VVVGAVGVGK, residues 8–16) is presented by the human leukocyte antigen HLA-A*11:01 on the surface of tumor cells[1][2][4][6]. This complex is not a naturally occurring receptor or enzyme, but rather a neoantigen presentation structure recognized by certain T-cell receptors. TCRs and immune therapies engineered to specifically bind this complex can effectively direct immune responses to cancer cells harboring the KRAS G12V mutation while sparing normal tissue, making it a key immunotherapeutic target under clinical and preclinical investigation[2][5][6][8]. Presentation by HLA-A*11:01 is essential for recognition, restricting applicability to HLA-matched patients. Challenges include possible TCR cross-reactivity with non-mutated self-peptides and the necessity for precise patient selection based on both KRAS mutation status and HLA genotype[5][6].

Other names

KRAS G12V/HLA-A11 complexKRAS G12V neoantigen-HLA-A*11:01 complexKRAS G12V 9-mer/HLA-A*11:01 complexKRAS G12V (VVVGAVGVGK)–HLA-A*11:01

TCR-based therapies: Engineered TCRs or TCR-mimic antibodies specifically recognize the KRAS G12V peptide presented on HLA-A*11:01, leading to targeted killing of cancer cells through cytotoxic T-cell engagement[2][8][5].